BLRX - BioLineRx Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.7500
+0.0300 (+1.10%)
As of 3:50PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close2.7200
Open2.7200
Bid2.7500 x 900
Ask2.7900 x 2900
Day's Range2.7200 - 2.7708
52 Week Range2.3200 - 15.1500
Volume21,921
Avg. Volume56,942
Market Cap28.224M
Beta (3Y Monthly)2.86
PE Ratio (TTM)N/A
EPS (TTM)-2.8350
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.00
Trade prices are not sourced from all markets
  • BioLineRx Begins Part 2 of Phase I/IIa Study on Solid Tumors
    Zacks

    BioLineRx Begins Part 2 of Phase I/IIa Study on Solid Tumors

    BioLineRx (BLRX) starts dosing the first patient in the part 2 of the phase I/IIa study evaluating AGI-134 for solid tumors.

  • PR Newswire

    BioLineRx Announces Dosing of First Patient in Part 2 of Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors

    TEL AVIV, Israel, Sept. 25, 2019 /PRNewswire/ -- BioLineRx Ltd. (BLRX) and (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology, announced today dosing of the first patient in part 2 of the Phase 1/2a clinical study for AGI-134, a novel compound that evokes a direct anti-tumor response, as well as a vaccine effect, via a unique, multi-arm mechanism that targets patient-specific tumor neoantigens. "Following the successful completion of part 1 of the study and determination of the recommended dose, we are pleased to announce the initiation of part 2 of the Phase 1/2a study of AGI-134, our second lead oncology product," said Philip Serlin, Chief Executive Officer of BioLineRx. "In preclinical trials, AGI-134 led to regression of established primary tumors, prevented growth of secondary tumors, and triggered a vaccine effect that may prevent the development of future metastases.

  • Benzinga

    The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 3) Ardelyx Inc (NASDAQ: ARDX ) ( reported positive results ...

  • PR Newswire

    BioLineRx Successfully Completes Dose-Escalation Part of Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors

    TEL AVIV, Israel, Sept. 3, 2019 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that it has successfully completed the dose-escalation part of the Phase 1/2a clinical study for AGI-134, a novel compound that evokes a direct anti-tumor response, as well as a vaccine effect, via a unique, multi-arm mechanism that targets patient-specific tumor neoantigens. The maximal tolerated dose was not reached and the recommended dose for part 2 of the study was determined. The ongoing Phase 1/2a study is a multicenter, open-label study expected to take place at approximately 15 sites in the US, UK and Israel.

  • PR Newswire

    BioLineRx Reports Second Quarter 2019 Financial Results and Provides Corporate Update

    On track for Phase 2 data read-out in pancreatic cancer by year-end 2019 Management to hold conference call today, August 6, at 10:00 am EDT TEL AVIV, Israel , Aug. 6, 2019 /PRNewswire/ -- BioLineRx Ltd. ...

  • Tenet Healthcare (THC) Q2 Earnings: What's in the Cards?
    Zacks

    Tenet Healthcare (THC) Q2 Earnings: What's in the Cards?

    Tenet Healthcare's (THC) second-quarter earnings are likely to suffer due to lower revenues.

  • PR Newswire

    BioLineRx to Report Second Quarter 2019 Results on August 6, 2019

    TEL AVIV, Israel, July 30, 2019 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended June 30, 2019 on Tuesday, August 6, 2019, before the US markets open. The Company will host a conference call on Tuesday, August 6, 2019 at 10:00 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer. The conference call will be available via webcast and can be accessed through the Investor Relations page of BioLineRx's website.

  • PR Newswire

    BioLineRx Announces Change in Ratio of American Depositary Shares to Ordinary Shares

    TEL AVIV, Israel, June 28, 2019 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that its Board of Directors has approved a change in the number of its ordinary shares represented by American Depositary Shares, issued by the Bank of New York Mellon as depositary, from 1 ordinary share per ADS to 15 ordinary shares per ADS. The change in exchange ratio for the ADSs will have the same effect as a 1-for-15 reverse stock split of the ADSs. The ADSs will continue to trade on the Nasdaq Capital Market.

  • PR Newswire

    BioLineRx to Present at the JMP Securities 2019 Life Sciences Conference

    TEL AVIV, Israel , June 13, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that its Chief Executive Officer, ...

  • BioLineRx (BLRX) Moves to Buy: Rationale Behind the Upgrade
    Zacks

    BioLineRx (BLRX) Moves to Buy: Rationale Behind the Upgrade

    BioLineRx (BLRX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • PR Newswire

    BioLineRx Reports First Quarter 2019 Financial Results and Provides Corporate Update

    On track for Phase 2 data read-outs in pancreatic cancer and consolidation AML by year-end 2019 Management to hold conference call today, May 14, at 10:00 am EDT TEL AVIV, Israel , May 14, 2019 /PRNewswire/ ...

  • PR Newswire

    BioLineRx to Report First Quarter 2019 Results on May 14, 2019

    Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel , May 7, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced ...

  • PR Newswire

    BioLineRx Announces FDA Approval of IND Application for AGI-134, a Novel Immunotherapy Anti-Cancer Vaccine for Solid Tumors

    TEL AVIV, Israel, May 7, 2019 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AGI-134, a novel immunotherapy anti-cancer vaccine for solid tumors. "We are pleased with the FDA's IND approval, which will enable us to expand our ongoing Phase 1/2a study, currently being carried out in the UK and Israel, to the US by the first half of 2020," said Philip Serlin, Chief Executive Officer of BioLineRx.

  • ACCESSWIRE

    Biotech News, What Milestones and Catalysts Could Drive BioLineRx Shares in 2019

    NEW YORK, NY / ACCESSWIRE / May 1, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report ...

  • PR Newswire

    BioLineRx Reports Year End 2018 Financial Results and Provides Corporate Update

    BL-8040 and AGI-134 oncology programs progressing, with multiple data read-outs expected in the next 12 months Management to hold conference call today, March 28, at 10:00 am EDT TEL AVIV, Israel , March ...

  • ACCESSWIRE

    Four Tech Stocks Sparking Activity on Wednesday

    Companies across the tech industry are pulling out all the stops to allocate resources for the development of innovative technology. Nowadays, consumers are outwardly vocal about the products they are interested in, and some companies in the tech sector have managed to meet the growing demands of consumers in the tech market. All in all, the future is largely unpredictable, but if the tech industry continues to develop exciting, advanced products and services to improve our quality of life, this could catalyze serious investor attention.

  • PR Newswire

    BioLineRx Announces Successful Engraftment Data From Phase 3 GENESIS Trial for BL-8040 in Multiple Myeloma Patients

    TEL AVIV, Israel, March 27, 2019 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that hematopoietic stem cells (HSCs) mobilized by BL-8040 in combination with granulocyte colony-stimulating factor (G-CSF) were successfully engrafted in all 11 patients participating in the Part 1, lead-in period of the  GENESIS trial, a double-blind, placebo-controlled Phase 3 trial comparing BL-8040 and G-CSF to G-CSF alone, in mobilization of HSCs for autologous transplantation in multiple myeloma patients. "Autologous HSC transplantation in multiple myeloma has been shown to improve overall survival compared to conventional chemotherapy.

  • PR Newswire

    BioLineRx to Report Annual 2018 Results on March 28, 2019

    Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel , March 21, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on ...

  • PR Newswire

    BioLineRx to Present at the 29th Annual Oppenheimer Healthcare Conference

    TEL AVIV, Israel , March 14, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that its Chief Executive Officer, ...

  • PR Newswire

    BioLineRx Announces Closing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants

    TEL AVIV, Israel, Feb. 8, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has closed its previously announced underwritten public offering of 28,000,000 American Depositary Shares ("ADSs"), each representing one of its ordinary shares, and warrants to purchase 28,000,000 ADSs, at a public offering price of $0.55 per ADS and accompanying warrant. The Company in-licenses novel compounds, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

  • PR Newswire

    BioLineRx Announces Pricing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants

    TEL AVIV, Israel, Feb. 6, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has priced an underwritten public offering of 28,000,000 American Depositary Shares ("ADSs"), each representing one of its ordinary shares, and warrants to purchase 28,000,000 ADSs, at a public offering price of $0.55 per ADS and accompanying warrant. Copies of the final prospectus supplement may also be obtained, when available, from Oppenheimer & Co. Inc., 85 Broad St., 26th Floor, New York, New York 10004, Attention: Syndicate Prospectus Department, or by telephone: (212) 667-8055 or by email: EquityProspectus@opco.com.

  • ACCESSWIRE

    Biotech on the Brink of Breaking Out

    HENDERSON, NV / ACCESSWIRE / February 5, 2019 / Below are some healthcare plays starting to gain investor interest that could breakout at any time. Do your research now. One of the best examples of the ...